Does USTEKINUMAB Cause Pulmonary fibrosis? 960 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 960 reports of Pulmonary fibrosis have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 1.1% of all adverse event reports for USTEKINUMAB.
960
Reports of Pulmonary fibrosis with USTEKINUMAB
1.1%
of all USTEKINUMAB reports
590
Deaths
595
Hospitalizations
How Dangerous Is Pulmonary fibrosis From USTEKINUMAB?
Of the 960 reports, 590 (61.5%) resulted in death, 595 (62.0%) required hospitalization, and 641 (66.8%) were considered life-threatening.
Is Pulmonary fibrosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 960 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Pulmonary fibrosis?
METHOTREXATE (2,912)
ADALIMUMAB (2,277)
RITUXIMAB (2,192)
ETANERCEPT (1,926)
TOCILIZUMAB (1,886)
ABATACEPT (1,828)
HYDROXYCHLOROQUINE (1,740)
LEFLUNOMIDE (1,731)
PREDNISONE (1,692)
INFLIXIMAB (1,595)
Which USTEKINUMAB Alternatives Have Lower Pulmonary fibrosis Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE